A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group.

@article{Miller1999ARD,
  title={A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group.},
  author={Paul D E Miller and Jacques P Brown and Ethel S. Siris and M. S. Hoseyni and D W Axelrod and Pirow J. Bekker},
  journal={The American journal of medicine},
  year={1999},
  volume={106 5},
  pages={513-20}
}
PURPOSE To compare the efficacy and tolerability of oral risedronate and etidronate for treatment of Paget's disease of bone. PATIENTS AND METHODS Patients from 12 centers in North America received risedronate 30 mg daily for 2 months (62 patients) or etidronate 400 mg daily for 6 months (61 patients) in a prospective, randomized, double-blind study. Serum alkaline phosphatase (the primary variable), serum bone-specific alkaline phosphatase, and urinary deoxypyridinoline concentrations were… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 42 extracted citations

Similar Papers

Loading similar papers…